R2D2 & C-17 New Landmarks in Canada’s Collaborative Pathways
Improving regulatory review of drugs and devices (R2D2) and protecting citizens from unsafe drugs (Bill C-17) are two critical components of the current pharmaceutical landscape in Canada and our 2018 DIA Canadian Annual Meeting, explain Melissa Hunt, Director of the Bureau of Metabolism, Oncology & Reproductive Sciences within the Therapeutic Products Directorate of Health Canada; and Loretta Del Bosco, Director of Regulatory Affairs Quality Assurance Operations, AbbVie Corporation, Canada.
Preconference Short Courses
October 29 | 8:00AM-12:00PMPolicy and Regulatory Development at the Health Products and Food Branch (HPFB): From Conception to Realization and the Role of Stakeholders
October 29 | 1:00PM-5:00PMRegulatory Renewal: Statistical Principles as Part of Regulatory Decision-Making
On-Demand Content Preview Webinar
What to Expect When You’re Inspected
Pharmaceutical and medical devices companies are frequently inspected by the authorities as a central element of supervision.
Have an account?